Laura E. Niklason - 15 Dec 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: President, CEO and Director, Director, 10%+ Owner
Signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Issuer symbol: HUMA
Transactions as of: 15 Dec 2022
Net transactions value: +$25,400
Form type: 4
Filing time: 19 Dec 2022, 19:27:32 UTC
Previous filing: 15 Dec 2022
Next filing: 19 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HUMA	Common Stock	Purchase	$25,400	+10,000	+0.86%	$2.54	1,170,240	15 Dec 2022	Direct	F1, F2
holding	HUMA	Common Stock						17,990,736	15 Dec 2022	By Ayabudge LLC
holding	HUMA	Common Stock						510,161	15 Dec 2022	By spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 1,522,500 shares of the Issuer's common stock on September 15, 2022, at a per share price of $4.00. The Reporting Person has paid the Issuer $14,604.95, representing the full amount of profit realized in connection with this purchase.
F2	The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.53 to $2.55. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 1,522,500 shares of the Issuer's common stock on September 15, 2022, at a per share price of $4.00. The Reporting Person has paid the Issuer $14,604.95, representing the full amount of profit realized in connection with this purchase.

The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.53 to $2.55. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.